Introduction from Drug peptide sells about Degarelix Acetate/214766-78-6
| English name | Degarelix |
| Chinese name | 地加瑞克 |
| CAS NO | 214766-78-6/934246-14-7/934016-19-0 |
| Peptide sequence | Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-Hor)-D4Aph(Cbm)-Leu-Lys(Ipr)-Pro-DAla-NH2 |
| Molecular formula | C82H103ClN18O16 |
| Molecular weight | 1632.26 |
| storage temperature | 2-8℃ |
| purity | ≥98% |
| Package | 1mg;5mg;10mg;50mg;100mg,1g or according to customer’s detail requirement. |
| Product English synonyms | FirMagon;Degarelix Acetate;N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropChemicalbookyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamideacetate |
What is Degarelix?
It is a synthetic gonadotropin-releasing hormone (GnRH) receptor antagonist, which reduces the release of gonadotropins and testosterone by reversibly binding to the GnRH receptors of the pituitary gland, thereby exerting an anti-prostate cancer effect.
Degarelix Acetate is an antagonist of prostate cancer GnRH
Its clinical effectiveness, safety, and long-term use of it have been verified by multiple clinical trials, and it is currently the most widely used GnRH antagonist.
For advanced prostate cancer bone metastases, it also showed good superiority. Studies have shown that patients with prostate cancer bone metastases who have been treated with degarelix for 1 year have significantly lower plasma alkaline phosphatase compared with GnRH agonist treatment.
S-ALP is often elevated and is often associated with bone metastasis. It can be used for androgen-dependent prostate cancer.
Mechanism of action
Degarelix is a gonadotropin-releasing hormone (GnRH) receptor inhibitor drug, which reversibly inhibits the pituitary GnRH receptor to reduce the release of gonadotropin and then inhibit the release of testosterone.
It slows the growth and progression of prostate cancer by inhibiting testosterone, which is essential for the continued growth of prostate cancer.
The initial stage of hormone treatment of prostate cancer to reduce testosterone concentration caused a sharp increase in testosterone concentration.
This initial stimulation of the hormone receptor can temporarily promote tumor growth instead of inhibiting it, while it does not.
Uses of Degarelix
Degarelix acetate is a gonadotropin releasing hormone receptor blocker, which has been approved for the treatment of advanced (hormone-dependent) prostate cancer in the United States and Europe and the United States and approved for the treatment of prostate cancer in Japan.
How to buy Degarelixin the U. S.
Remetide Peptide Supplier specializes in the production and sales of peptides in the USA, as well as Professional Drug peptide R&D. Feel free to contact us if you have any questions or inquiries about Degarelixin Peptides.
Hot line:+19498788363
Wechat:americhina
Email:amin@remetide.com